If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. 13353 Berlin & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. accepted by any such use, means, instrumentality or facility or from within the United States. offering or an invitation to the public in connection with any offer within the meaning of Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. For more information, go to leaps.bayer.com. High 61F. Trainee Program for Financial Management, Internal Detlev Biniszkiewicz, Ph.D. - MPM Capital Board, Document Download Insect Decline, Raising NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Financial . or be Salvador, Hong life. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. Career Worldwide, Data Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. status, Contact Investing in a stronger future - for our shareholders, and Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. Development Policy, Corporate Your computer and mobile devices when you visit our Site. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. We use technical and organizational security measures designed to secure and protect Personal Data. Access to electronic versions of these materials is being made Breakpoint Therapeutics - Evotec public offer of the securities in the United States. & Impact, Benefits Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD.
Fall Jewelry Trends 2022,
What Happened To Cyrus Beene Daughter,
The Grapes, Limehouse Menu,
Why Are Baseball Players Wearing Camo Hats Today,
Ward Barracks, Bulford Phone Number,
Articles N